These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1514 related articles for article (PubMed ID: 25311082)
1. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
3. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456 [TBL] [Abstract][Full Text] [Related]
6. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV Zhang YY; Song L; Zhao MX; Hu K Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646 [TBL] [Abstract][Full Text] [Related]
10. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729 [TBL] [Abstract][Full Text] [Related]
11. Metabolic tumour area: a novel prognostic indicator based on Cui S; Xin W; Wang F; Shao X; Shao X; Niu R; Zhang F; Shi Y; Liu B; Gu W; Wang Y BMC Cancer; 2024 Jul; 24(1):895. PubMed ID: 39054508 [TBL] [Abstract][Full Text] [Related]
12. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438 [TBL] [Abstract][Full Text] [Related]
13. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen? Jiang C; Ding C; Xu J; Teng Y; Chen J; Wang Z; Zhou Z Clin Nucl Med; 2021 Jan; 46(1):1-7. PubMed ID: 33181743 [TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392 [TBL] [Abstract][Full Text] [Related]
15. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma. Sun Y; Lu P; Yu L Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649 [TBL] [Abstract][Full Text] [Related]
17. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736 [TBL] [Abstract][Full Text] [Related]
18. Value of Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996 [TBL] [Abstract][Full Text] [Related]
19. [Value of Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248 [TBL] [Abstract][Full Text] [Related]
20. [ Gui J; Li M; Xu J; Zhang X; Mei H; Lan X Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]